News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK Scientists Report Successful Testing of Aradigm Corporation (ARDM)'s Inhaled Liposomal Ciprofloxacin in Q Fever


9/20/2012 9:28:39 AM

HAYWARD, Calif.--(BUSINESS WIRE)--UK scientists from the Health Protection Agency (HPA) and Defence Science and Technology Laboratory (Dstl) reported this week at the University of Southampton’s Wessex Life Sciences Alliance Conference the successful testing of Aradigm’s inhaled liposomal ciprofloxacin against Coxiella burnetii in a mouse model of this virulent infection. This work was conducted as part of the collaborative consortium that Aradigm Corporation formed with HPA and Dstl to evaluate the efficacy of Aradigm’s inhaled liposomal ciprofloxacin against high threat microbial agents.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES